Overview of Different Indicators: American Tower Corporation (REIT) (AMT), Exact Sciences Corporation (EXAS)

You should consider shares of American Tower Corporation (REIT) (NYSE:AMT) and Exact Sciences Corporation (NASDAQ:EXAS) if you are looking for a great stocks to invest in. Starting with the AMT shares, which traded at $214.03 at the close of the recent session, dropping -0.41%. On Friday, the company’s shares shed -$0.88 from its value which represented in intraday trading. The stock is now 32.12% higher in year-to-date (YTD) trading. AMT’s intraday high was $215.795 while its lowest price touched $213.68. The stock’s 52-week high price is $242.00, which means the current price is at -11.56%. In terms of trading activity, the daily trading volume fell to 654257 against 200-day average trading volume of 1,734,432 shares.

What are analyst forecasts for American Tower Corporation (REIT) (NYSE:AMT)?

At a consensus rating of 3.64, AMT is trending as a streaking Moderate Buy, as it has been the case a month ago when 15 analysts called it a Moderate Buy. Two months ago, 15 analysts recommended, on average, that AMT stock is a Moderate Buy. The Financial company’s shares’ overall bearish trend saw it close higher on Friday compared to its opening price of $214.91 on the day.

Forecasts for American Tower Corporation (REIT) (NYSE:AMT) give the stock a fair value for the growth from its last price.

The consensus among 17 analysts is that it is a good time for one to Overweight in the American Tower Corporation (REIT). 5 analysts rate AMT as a Buy, with 0 of 17 analysts rate it as a Sell. 0 have valued the stock as Overweight and 11 have recommended that investors Hold.

American Tower Corporation (REIT) (NYSE:AMT) Upgrades and Downgrades

In terms of rating changes, Citigroup on September 04, 2019, Reiterated American Tower Corporation (REIT) (AMT) at Neutral. They believe the stock could reach $240 in the near term. Analysts at UBS have assigned a Neutral rating for the stock in their research note on June 07, 2019 with an estimated price target of $222. Moreover, Wells Fargo analysts issued a rating of Market Perform for the stock on April 15, 2019, giving it a price target of $196 for the next 12 months. On March 19, 2019, the stock earned a Buy rating due to an analyst call from BofA/Merrill, while analysts from Oppenheimer on February 28, 2019 suggested that the stock is Perform.

Exact Sciences Corporation (NASDAQ:EXAS) adds -$0.54 on Friday

The EXAS stock has risen 28.38% year-to-date and is currently trading at $81.01, which is -34.66% below its 52-week high. The company shares lost -0.66% on the day and have risen nearly 52.68% off a low hit. At current levels, Exact Sciences Corporation has a valuation of about $723.70M. As of 11/29/19, this stock has risen 2.52% during the week and closed at $81.55 in the previous session. However, recent Exact Sciences Corporation stock performance shows that EXAS shares are -3.57% down over the last month, and -32.05% down for the last three months.

Earnings per share (EPS) estimates for the current quarter are -$0.49, with the trailing 12-month share earnings at -$1.71. The ratio is expected to be down by -14.70% for the current year 2019 and 77.40% for next year. Over the next 5-year period, earnings per share will be 20.00%. But will the EXAS stock surprise in the current quarter results, where the -$0.31 actual EPS reported on 9/29/2019 surprised by 24.40% or was higher by $0.1 from the estimated -$0.41.

Sales Growth to climb 99.20% for the year

How well will Exact Sciences Corporation perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $225.59M and $296.6M in current quarter sales. The consensus estimated for the current quarter is $240.75M from sales. Forecasts for this fiscal year are between $806.31M and $877.4M and the consensus estimate for sales is at $821.38M. EXAS has its next quarter sales estimates at between $353.41M and $380.3M, with the quarter-over-quarter growth estimates at 126.80% and the annual growth forecast for the year at 99.20%.

Who owns shares in Exact Sciences Corporation (EXAS)?

Let’s briefly focus on the share ownership of the Exact Sciences Corporation (NASDAQ:EXAS) stock, where we find that 90.27% of shares are held by institutions. Vanguard Group, Inc. (The) tops the list of institutional owners as it is holding 11.86 million shares or 9.14% of shares outstanding. Price (T.Rowe) Associates Inc and Blackrock Inc. held 11.62 million and 7.05 million representing 8.95% and 5.43% respectively at the close of the last trading session. As of Sep 29, 2019, Jennison Associates LLC accounted for 5.42 million shares at over 490.21 million. This represented 4.18% of shares outstanding. JP Morgan Chase & Company held 5.15 million shares at over 465.81 million representing 3.97% of shares outstanding.

EXAS Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at Exact Sciences Corporation (EXAS), a total of 103547 shares have been sold by insiders over the last 6 months while 100804 shares were added in the same time span. On 1/25/2019, President & Chief Executive Officer by the name Conroy Kevin T sold 181250.0 shares worth $14.8 million at the price of $81.90 per share. Filings also show that Coward D Scott sold a total of 99231.0 shares on 1/24/2019 valued at $7.8 million. Since the last insider activity, the company’s share price has climbed 2.83%.